Company intelligence / Profile preview

Ritter Pharmaceuticals

Los Angeles, California, United States

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Ritter Pharmaceuticals' lead candidate, RP-G28, completed a Phase 2b clinical trial for reducing symptoms of lactose intolerance by stimulating the growth of lactose-metabolizing bacteria in the colon. The treatment demonstrated symptom reduction, but the company has not advanced to Phase 3 or commercialization as of the latest updates and is no longer active or publicly traded.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Medpace (CRO for pivotal clinical studies)

Beyond the preview

Go deeper on Ritter Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ritter Pharmaceuticals.

Explore the full profile